IR-Med Inc.

Equities

IRME

US46265R1032

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets 12:08:30 2024-04-26 pm EDT			5-day change	1st Jan Change
0.9 ^USD	-5.26%		-5.26%	-21.74%

Apr. 05	IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	CI
Apr. 01	IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

IR-Med Inc. Announces Cessation of Tzur Di-Cori Pursuant as Chief Executive Officer

February 28, 2024 at 04:05 pm EST

On February 22, 2024, the board of directors of IR-Med Inc. terminated the employment of Tzur Di-Cori pursuant to which he ceased serving as the Company?s Chief Executive Officer, effective immediately.

Latest news about IR-Med Inc.

IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	Apr. 05	CI
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
IR-Med Inc. and I.R Med Ltd. Appoints Aharon Klein as Interim Chief Executive Officer	Mar. 05	CI
IR-Med Inc. Announces Cessation of Tzur Di-Cori Pursuant as Chief Executive Officer	Feb. 28	CI
IR-Med Inc. Announces Resignation of Inna Martin as Director	Feb. 23	CI
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe? Device at NPIAP 2024 Annual Conference on February 16	Feb. 13	CI
IR-Med Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
IR-MED Announces Executive Changes Effective as of October 15, 2023	23-10-04	CI
Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024	23-09-26	CI
IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board	23-09-13	CI
IR-Med Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Ir-Med Inc. Announces Interim Results from A Clinical Study of Pressuresafe	23-07-17	CI
IR-Med Inc. Appoints Lynn Eschenbacher to its Advisory Board	23-06-07	CI
IR-Med Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
IR-Med Inc. Auditor Raises 'Going Concern' Doubt	23-03-28	CI
IR-Med Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
IR-Med Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
IR-Med Inc. announced that it has received $0.425002 million in funding	22-07-30	CI
IR-Med, Inc. Announces Resignation of David Lazar to Its Board of Directors	22-07-01	CI
IR-Med Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
IR-Med Announces Appointment of Moshe Gerber as Chief Executive Officer	22-05-10	CI
IR-Med Inc. Announces Resignation of Rom Eliaz as Chief Executive Officer	22-04-29	CI
IR-Med Inc. announced that it has received $3.2 million in funding	22-04-10	CI
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI

Chart IR-Med Inc.

Duration

Period

More charts

Company Profile

IR-Med, Inc. is a development-stage medical device company. The Company develops non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The Companyâs devices allow healthcare professionals to detect and measure different molecules in the blood and in human tissue in real-time without any invasive procedures. Its initial product candidates are in various stages of development. It is focused on two principal medical devices: PressureSafe and Nobiotics. PressureSafe is a handheld optical monitoring device that is being developed to support the early detection of pressure injuries (PI) to the skin and underlying tissue, primarily caused by prolonged pressure associated with bed confinement. Nobiotics is an otoscope, which is designed to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media) is of a bacterial origin.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
IR-MED INC.	-21.74%	62.98M
ABBOTT LABORATORIES	-3.67%	186B
MEDTRONIC PLC	-2.47%	107B
BECTON, DICKINSON AND COMPANY	-3.82%	67.44B
DEXCOM, INC.	+3.19%	50.03B
CENCORA, INC.	+16.06%	47.81B
HOYA CORPORATION	+4.79%	41.03B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.47%	26.85B
WEST PHARMACEUTICAL SERVICES, INC.	+2.30%	25.82B
ZIMMER BIOMET HOLDINGS, INC.	-0.76%	25.01B

Other Medical Equipment, Supplies & Distribution

IR-Med Inc.

Equities

IRME

US46265R1032

Medical Equipment, Supplies & Distribution

IR-Med Inc. Announces Cessation of Tzur Di-Cori Pursuant as Chief Executive Officer

Latest news about IR-Med Inc.

Chart IR-Med Inc.

Company Profile

Income Statement Evolution

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution